This week’s headlines include, pharmaceutical sales to grow through 2020, EMD Serono and Mersana join on ADCs, immunotherapy prolongs survival in melanoma trial, report finds R&D spending outpacing revenue growth, top 10 vaccines sales for 2013, world’s largest study on Dementia, Mesoblast product shows promise in trial.
Cell Culture Events
The Bioprocessing Summit – August 18-22, 2014 – Renaissance Waterfront Hotel – Boston, MA
“For the first time since the global financial crisis began in mid-2007, spending by biotechnology companies on research and development grew at a faster rate than revenue, according to consulting firm Ernst & Young.”
If you like this story, please see our blog titled “CHO Cell Culture – Ten Tips from the Experts on Expression, Media and Bioprocessing”
“Recent advances in the quest for vaccines against MERS, SARS, and other coronaviruses have vaccines front and center in the news again. More ominously, scientists have demonstrated that circulating avian influenza viruses contain all the genetic ingredients needed to lead to the emergence of a virus similar to the deadly 1918 influenza virus.”
If you like this story, please see our blog titled “Reducing Footprints and Increasing Output in Adherent Cell Culture”
“The world’s biggest dementia study was launched in the U.K. Thursday, and will analyze data from more than two million people to try and find new treatments for the little-understood disease, including its commonest form, Alzheimer’s.”
If you like this story, please see our blog titled “Single-use Technology for Microbial Fermentation”
“Worldwide prescription drug sales are expected to exceed the trillion dollar mark by 2020, according to Evaluate’s “World Preview 2014, Outlook to 2020” report released Wednesday. Evaluate projects the pharma industry to grow, on average, 5.1% per year from 2013 to 2020.”
If you like this story, please see our blog titled “PCR Release Testing for Mycoplasmas Gaining Ground versus Conventional Methods”
“A late stage trial testing Bristol-Myers Squibb Co’s cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.”
If you like this story, please see our blog titled “Using Induced Pluripotent Stem Cells to Model Human Disease”
